Medical - Diagnostics & Research
Compare Stocks
2 / 10Stock Comparison
PSNL vs GH
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
PSNL vs GH — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $542M | $11.53B |
| Revenue (TTM) | $52M | $903M |
| Net Income (TTM) | $-81M | $-399M |
| Gross Margin | -3.0% | 63.8% |
| Operating Margin | -168.4% | -49.0% |
| Total Debt | $32M | $1.68B |
| Cash & Equiv. | $124M | $378M |
PSNL vs GH — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Personalis, Inc. (PSNL) | 100 | 51.3 | -48.7% |
| Guardant Health, In… (GH) | 100 | 102.1 | +2.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PSNL vs GH
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PSNL is the clearest fit if your priority is efficiency.
- -24.3% ROA vs GH's -31.2%, ROIC -40.7% vs -35.0%
GH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.86
- Rev growth 32.9%, EPS growth 6.7%, 3Y rev CAGR 29.8%
- 186.5% 10Y total return vs PSNL's -78.7%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 32.9% revenue growth vs PSNL's -100.0% | |
| Quality / Margins | -44.2% margin vs PSNL's -155.4% | |
| Stability / Safety | Beta 0.86 vs PSNL's 2.75 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +120.0% vs PSNL's +51.7% | |
| Efficiency (ROA) | -24.3% ROA vs GH's -31.2%, ROIC -40.7% vs -35.0% |
PSNL vs GH — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
PSNL vs GH — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
GH leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GH is the larger business by revenue, generating $903M annually — 17.3x PSNL's $52M. GH is the more profitable business, keeping -44.2% of every revenue dollar as net income compared to PSNL's -155.4%. On growth, GH holds the edge at +38.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $52M | $903M |
| EBITDAEarnings before interest/tax | -$80M | -$402M |
| Net IncomeAfter-tax profit | -$81M | -$399M |
| Free Cash FlowCash after capex | -$79M | -$262M |
| Gross MarginGross profit ÷ Revenue | -3.0% | +63.8% |
| Operating MarginEBIT ÷ Revenue | -168.4% | -49.0% |
| Net MarginNet income ÷ Revenue | -155.4% | -44.2% |
| FCF MarginFCF ÷ Revenue | -151.9% | -29.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +38.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -13.0% | +15.9% |
Valuation Metrics
GH leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $542M | $11.5B |
| Enterprise ValueMkt cap + debt − cash | $449M | $12.8B |
| Trailing P/EPrice ÷ TTM EPS | -6.67x | -27.79x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 11.74x |
| Price / BookPrice ÷ Book value/share | 2.07x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
GH leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), GH scores 5/9 vs PSNL's 4/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -31.1% | — |
| ROA (TTM)Return on assets | -24.3% | -31.2% |
| ROICReturn on invested capital | -40.7% | -35.0% |
| ROCEReturn on capital employed | -33.0% | -29.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.12x | — |
| Net DebtTotal debt minus cash | -$92M | $1.3B |
| Cash & Equiv.Liquid assets | $124M | $378M |
| Total DebtShort + long-term debt | $32M | $1.7B |
| Interest CoverageEBIT ÷ Interest expense | -5215.45x | -117.27x |
Total Returns (Dividends Reinvested)
GH leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GH five years ago would be worth $6,853 today (with dividends reinvested), compared to $2,821 for PSNL. Over the past 12 months, GH leads with a +120.0% total return vs PSNL's +51.7%. The 3-year compound annual growth rate (CAGR) favors GH at 57.7% vs PSNL's 38.8% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -22.7% | -9.3% |
| 1-Year ReturnPast 12 months | +51.7% | +120.0% |
| 3-Year ReturnCumulative with dividends | +167.4% | +292.1% |
| 5-Year ReturnCumulative with dividends | -71.8% | -31.5% |
| 10-Year ReturnCumulative with dividends | -78.7% | +186.5% |
| CAGR (3Y)Annualised 3-year return | +38.8% | +57.7% |
Risk & Volatility
GH leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
GH is the less volatile stock with a 0.86 beta — it tends to amplify market swings less than PSNL's 2.75 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GH currently trades 76.4% from its 52-week high vs PSNL's 52.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.75x | 0.86x |
| 52-Week HighHighest price in past year | $11.50 | $120.74 |
| 52-Week LowLowest price in past year | $3.84 | $36.36 |
| % of 52W HighCurrent price vs 52-week peak | +52.8% | +76.4% |
| RSI (14)Momentum oscillator 0–100 | 40.0 | 51.9 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 1.9M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PSNL as "Buy" and GH as "Buy". Consensus price targets imply 85.3% upside for PSNL (target: $11) vs 44.3% for GH (target: $133).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $11.25 | $133.14 |
| # AnalystsCovering analysts | 12 | 30 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
GH leads in 5 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics.
PSNL vs GH: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PSNL or GH a better buy right now?
For growth investors, Guardant Health, Inc.
(GH) is the stronger pick with 32. 9% revenue growth year-over-year, versus -100. 0% for Personalis, Inc. (PSNL). Analysts rate Personalis, Inc. (PSNL) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PSNL or GH?
Over the past 5 years, Guardant Health, Inc.
(GH) delivered a total return of -31. 5%, compared to -71. 8% for Personalis, Inc. (PSNL). Over 10 years, the gap is even starker: GH returned +186. 5% versus PSNL's -78. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PSNL or GH?
By beta (market sensitivity over 5 years), Guardant Health, Inc.
(GH) is the lower-risk stock at 0. 86β versus Personalis, Inc. 's 2. 75β — meaning PSNL is approximately 219% more volatile than GH relative to the S&P 500.
04Which is growing faster — PSNL or GH?
By revenue growth (latest reported year), Guardant Health, Inc.
(GH) is pulling ahead at 32. 9% versus -100. 0% for Personalis, Inc. (PSNL). On earnings-per-share growth, the picture is similar: Personalis, Inc. grew EPS 33. 6% year-over-year, compared to 6. 7% for Guardant Health, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PSNL or GH?
Guardant Health, Inc.
(GH) is the more profitable company, earning -42. 4% net margin versus -155. 4% for Personalis, Inc. — meaning it keeps -42. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GH leads at -44. 5% versus -168. 4% for PSNL. At the gross margin level — before operating expenses — GH leads at 64. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PSNL or GH?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PSNL or GH better for a retirement portfolio?
For long-horizon retirement investors, Guardant Health, Inc.
(GH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 86), +186. 5% 10Y return). Personalis, Inc. (PSNL) carries a higher beta of 2. 75 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GH: +186. 5%, PSNL: -78. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PSNL and GH?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PSNL is a small-cap quality compounder stock; GH is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.